Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

NeuroBo Pharmaceuticals Q2 EPS $(1.85) Misses $(1.12) Estimate

Author: Benzinga Newsdesk | August 14, 2024 07:15am
NeuroBo Pharmaceuticals (NASDAQ:NRBO) reported quarterly losses of $(1.85) per share which missed the analyst consensus estimate of $(1.12) by 65.18 percent. This is a 12233.33 percent decrease over losses of $(0.01) per share from the same period last year.

Posted In: NRBO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist